Leveraging Routine Blood Tests, Plasma pTau‐217, and Machine Learning for Enhanced Detection and Monitoring of Preclinical Alzheimer's Disease

Abstract

Background: Preclinical Alzheimer's disease (AD) develops 15–20 years before symptom onset. This study aimed to develop models to enhance the detection and monitoring of preclinical AD. Method: A retrospective cohort study was conducted based on data from the A4 study, spanning February 28, 2014, to June 8, 2023.